Scottsdale to Cook Up Ibogaine and Ecstasy for Labs
Published Date: 2/18/2025
Notice
Summary
Scottsdale Research Institute wants to make big batches of two powerful drugs, Ibogaine and MDMA, for research only. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 21, 2025. This move could boost scientific studies but doesn’t change drug sales or use rules.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Application to Bulk‑Manufacture Ibogaine and MDMA
On January 8, 2025, Scottsdale Research Institute (12815 North Cave Creek Road, Phoenix, AZ 85022) applied to be registered as a bulk manufacturer of Ibogaine (code 7260) and 3,4‑Methylenedioxymethamphetamine (MDMA, code 7405), both listed as Schedule I. The company says it plans to bulk manufacture these substances only for internal research and analytical development purposes, and that no other activities for these drug codes would be authorized if registered.
Opportunity to Submit Comments or Request Hearing
Registered bulk manufacturers of the affected classes and applicants may submit electronic comments or objections, or file a written request for a hearing, on the Scottsdale Research Institute application on or before April 21, 2025. Comments must be submitted through https://www.regulations.gov and commenters will receive a Comment Tracking Number upon submission.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-02738, Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to become a big-time maker of special research drugs called psilocybin and psilocyn. They plan to import these substances to help with science and medicine, not to sell or distribute them. If you have thoughts or want a hearing, you’ve got until April 21, 2025, to speak up!
Next: 2025-02740, Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals wants to officially make big batches of three strong medicines: Methylphenidate, Hydromorphone, and Tapentadol. This move affects drug makers and users by ensuring these drugs are made safely and legally. People can share their thoughts or ask for a hearing by April 21, 2025, so don’t miss the deadline!